Published in J Gastrointest Surg on May 02, 2002
Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol (2003) 1.53
Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J Gastroenterol (2009) 0.86
Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma. Chin J Cancer Res (2011) 0.78
Combination percutaneous and intraarterial therapy for the treatment of hepatocellular carcinoma: a review. Semin Intervent Radiol (2010) 0.78
Combined transarterial chemoembolization and arterial administration of Bletilla striata in treatment of liver tumor in rats. World J Gastroenterol (2003) 0.77
HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med (2016) 0.75
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
Benefit of systematic segmentectomy of the hepatocellular carcinoma: revisiting the dye injection method for various portal vein branches. Ann Surg (2013) 2.02
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med (2012) 1.59
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
Analysis of infection risk following covered stent exclusion of pseudoaneurysms in prosthetic arteriovenous hemodialysis access grafts. J Vasc Interv Radiol (2011) 1.43
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother (2004) 1.40
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res (2011) 1.38
Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med (2007) 1.33
Dendritic cell-based immunotherapy. Int Rev Immunol (2006) 1.30
Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery (2002) 1.29
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys (2005) 1.28
Toward protecting the safety of participants in clinical trials. Control Clin Trials (2003) 1.23
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat (2012) 1.21
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg (2007) 1.19
Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology (2012) 1.16
Live donor liver transplantation in high MELD score recipients. Ann Surg (2010) 1.14
Increasing vaccine potency through exosome antigen targeting. Vaccine (2011) 1.13
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther (2008) 1.13
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther (2007) 1.12
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.10
Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract (2009) 1.10
[Four cases of hepatic fascioliasis mimicking cholangiocarcinoma]. Korean J Hepatol (2005) 1.09
Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg (2007) 1.09
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther (2007) 1.07
Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun (2005) 1.07
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist (2011) 1.05
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest (2013) 1.02
Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival. Genes Chromosomes Cancer (2011) 1.02
Histological and molecular evaluation of patient-derived colorectal cancer explants. PLoS One (2012) 1.01
The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology (2009) 1.01
Can genetic variations predict HCV treatment outcomes? J Hepatol (2008) 1.01
Laparoscopic major liver resection in Korea: a multicenter study. J Hepatobiliary Pancreat Sci (2013) 1.01
A graft to body weight ratio less than 0.8 does not exclude adult-to-adult right-lobe living donor liver transplantation. Liver Transpl (2009) 1.00
An imported case of cystic echinococcosis in the liver. Korean J Parasitol (2012) 1.00
Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol (2008) 0.99
Gastrointestinal bleeding in adult patients with Meckel's diverticulum: the role of technetium 99m pertechnetate scan. South Med J (2002) 0.98
Carcinosarcoma of the liver: a case report. Korean J Radiol (2007) 0.98
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med (2012) 0.96
The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol (2003) 0.96
Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother (2009) 0.95
Dendritic cell vaccines. Front Biosci (2007) 0.95
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res (2011) 0.95
[A case of primary small cell carcinoma in the common bile duct]. Korean J Gastroenterol (2004) 0.95
Increased ischemic injury in old mouse liver: an ATP-dependent mechanism. Liver Transpl (2007) 0.95
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol (2011) 0.94
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Res (2010) 0.94
Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2010) 0.93
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol (2010) 0.93
Transgenic mice overexpressing human Bcl-2 are resistant to hepatic ischemia and reperfusion. J Hepatol (2002) 0.93
Inflammatory pseudotumors mimicking intrahepatic cholangiocarcinoma of the liver; IgG4-positivity and its clinical significance. J Hepatobiliary Pancreat Sci (2012) 0.93
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med (2009) 0.93
Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res (2011) 0.92
Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. J Oncol Pharm Pract (2010) 0.91
NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother (2005) 0.91
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J Clin Invest (2010) 0.91
Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review. Cancer (2006) 0.90
Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation. Liver Transpl (2009) 0.89
[Inflammatory pseudotumor of liver--a clinical review of 15 cases]. Korean J Hepatol (2006) 0.89
Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling. J Korean Med Sci (2011) 0.89
Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol (2002) 0.89
Provocative mesenteric angiography for lower gastrointestinal hemorrhage: results from a single-institution study. J Vasc Interv Radiol (2010) 0.89
Role of regulatory T cells in the promotion of transplant tolerance. Liver Transpl (2012) 0.88
Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report. Case Rep Oncol (2010) 0.88
Immune signatures predict prognosis in localized cancer. Cancer Invest (2010) 0.88
The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. J Hepatol (2010) 0.88
Cancer care quality measures: diagnosis and treatment of colorectal cancer. Evid Rep Technol Assess (Full Rep) (2006) 0.87
The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma. PLoS One (2013) 0.87
Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. Int Immunol (2005) 0.87
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys (2007) 0.87
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. Breast Cancer Res (2012) 0.87
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.86
Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature). J Eval Clin Pract (2007) 0.86
Gene therapy for lung cancer. J Cell Biochem (2006) 0.85
Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther (2007) 0.85
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer (2011) 0.84
Subnormothermic ex vivo liver perfusion reduces endothelial cell and bile duct injury after donation after cardiac death pig liver transplantation. Liver Transpl (2014) 0.84
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Invest New Drugs (2013) 0.84
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.84
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother (2015) 0.84
The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. Rambam Maimonides Med J (2010) 0.83
Protein interferon-stimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis. J Virol (2014) 0.83
Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. J Cancer Res Clin Oncol (2013) 0.83
Recent clinical progress in virus-based therapies for cancer. Expert Opin Biol Ther (2006) 0.83
A propensity score-matched case-control comparative study of laparoscopic and open liver resection for hepatocellular carcinoma. J Laparoendosc Adv Surg Tech A (2014) 0.83
Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis C. Can J Gastroenterol (2013) 0.83
Living donor liver transplantation in patients with portal vein thrombosis: a survey and review of technical issues. Transplantation (2002) 0.83
MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. J Proteomics (2011) 0.82
Treatment-related toxicity and supportive care in metastatic colorectal cancer. J Support Oncol (2010) 0.82
Role of natural killer cell function in dendritic cell-based vaccines. Expert Rev Vaccines (2006) 0.82
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res (2009) 0.82
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med (2013) 0.82
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. Cancer Immunol Immunother (2012) 0.81